Resolute Onyx Zotarolimus-Eluting Coronary Stent System RX and OTW, Onyx Frontier Zotarolimus-Eluting Coronary Stent S
FDA premarket approval P160043/S069 · decided 2023-06-02
Approval details
- PMA number
- P160043
- Supplement
- S069
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- Resolute Onyx Zotarolimus-Eluting Coronary Stent System RX and OTW, Onyx Frontier Zotarolimus-Eluting Coronary Stent S
- Generic name
- Coronary drug-eluting stent
- Applicant
- Medtronic Vascular
- Date received
- 2023-05-24
- Decision date
- 2023-06-02
- Days to decision
- 9 days
- Decision code
- OK30
- Product code
- NIQ
- Advisory committee
- Cardiovascular
- Expedited review
- No
- Location
- Santa Rosa, CA
- Statement
- Transfer of component extrusion operations lines 5, 9, and 13 from the Medtronic Santa Rosa site to the Medtronic Danvers site.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.